- cafead   Dec 13, 2022 at 10:52: AM
via While more pharmas big and small are pursuing “off-the-shelf” CAR-T therapies, Novartis has been blazing its own trail. The Swiss drugmaker has been fine-tuning its T-Charge platform to speed up the process by ensuring most of the CAR T-cell expansion occurs within a patient’s body.
article source
article source